All In MedTech

Device Trial Radar · NCT02478112

Use of a Biodegradable Balloon for the Treatment of Prostate Cancer by Intensity Modulated Radiotherapy (BioPro-RCMI)

Multicentre Study Evaluating the Use of a Biodegradable Balloon for the Treatment of Prostate Cancer (of Intermediate Risk) by Intensity Modulated Conformal Radiotherapy (BioPro-RCMI)

Last checked: Nov 20, 2026Latest source record: Mar 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

24

Actual

Start

Nov 25, 2016

Primary completion

May 28, 2018

Study completion Sep 7, 2020

Sponsor

Lead sponsor
Centre Oscar LambretAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Aquilab SAS
First posted
Jun 23, 2015

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The benefit of dose escalation in radiotherapy (RT) for biochemical control of prostate cancer is a clearly established fact based on the results of different published prospective trials. This benefit, acquired with three-dimensional conformal radiation technique is counterbalanced by an increase in urinary and gastrointestinal toxicity. The joint progress of dose planning systems and multileaf collimators (MLC) technology have enabled the Intensity Modulated Radiation Therapy (IMRT). Recently the contribution of "spacers" positioned in the septum between the rectum and the prostate could improve the functional results of IMRT in terms of rectal toxicity. The aim of the investigators study is to assess the dosimetric gain from the contribution of the implantable BioProtect balloon on organs at risk.

Conditions

  • Prostate Cancer

Interventions

  • Biodegradable balloon implantDevice

    Implantation under general anaesthesia of a biodegradable balloon before radiation therapy for prostate cancer

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dosimetric gain from the contribution of the balloon on organs at riskTime frame: 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinique Pasteur

    Toulouse, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.